Gilead Ends Study of Leukemia Treatment Early After Positive Interim Results NASDAQ It demonstrated " highly statistically significant efficacy" in patients receiving the treatment receiving idelalisib plus rituximab compared with those receiving rituximab alone, the company said. The company said it told the Food and Drug ... |
